Zacks Research Weighs in on Zoetis’ Q3 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Stock analysts at Zacks Research cut their Q3 2025 earnings per share estimates for Zoetis in a research report issued to clients and investors on Wednesday, October 23rd. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.61 per share for the quarter, down from their previous estimate of $1.63. The consensus estimate for Zoetis’ current full-year earnings is $5.83 per share.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the prior year, the business posted $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year.

Other equities analysts have also issued reports about the company. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Trading Down 4.0 %

NYSE:ZTS opened at $181.52 on Friday. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a 50-day moving average price of $189.23 and a two-hundred day moving average price of $177.58. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The firm has a market cap of $82.24 billion, a price-to-earnings ratio of 35.52, a price-to-earnings-growth ratio of 2.94 and a beta of 0.89.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. Zoetis’s payout ratio is 33.86%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Prevail Innovative Wealth Advisors LLC raised its holdings in Zoetis by 24.5% during the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after acquiring an additional 3,738 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Zoetis by 58.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock worth $7,095,000 after purchasing an additional 15,491 shares in the last quarter. Duality Advisers LP boosted its stake in Zoetis by 43.7% in the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock worth $6,877,000 after purchasing an additional 12,359 shares during the period. M&G Plc bought a new stake in shares of Zoetis during the first quarter valued at about $19,819,000. Finally, Cetera Investment Advisers lifted its holdings in shares of Zoetis by 275.2% in the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock worth $16,259,000 after buying an additional 70,476 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.